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1. Introduction 
Down syndrome (DS) is increased frequency of some common dermatoses and associated 
with rare dermatological disorders. With the increasing life span and number of DS patients 
in the population, dermatologists are more likely to encounter skin manifestations 
associated with DS. Subjects with DS have high rates of infections and autoimmune 
phenomena. The immunological disturbances in DS (High IgG and low IgM levels, reduced 
total T-lymphocyte numbers, high CD8+ and low CD4+ count, decreased chemotaxis,…) 
could be implicated in some higher cutaneous manifestations.   
In this chapter, it has been exposed the dermatological disorders associated with DS. Very 
few studies in the literature have studied dermatological manifestations of DS. Newer 
reports are mostly in the form of case reports highlighting the rare dermatological findings. 
Dermatologic manifestation in DS has been studied in 6 major surveys but the results are 
not concordant. These studies differ in some aspects (age range, living conditions of the 
study group,...). Daneshpazhooh et al studied 100 children with DS with a mean age of 11.2 
years; Carter and Jegasothy examined 213 institutionalized patients with ages between 12 
and 48 years old; Ercis et al studied 71 children who live with their families; Polenghi et al 
observed adults with ages between 14 and 53 years old; Schepis et al examined 203 patients 
from infancy till adulthood with a mean age of 11.7 years; and  Sureshbabu et al  studied 95 
patients with a mean age of 11.9 years, ranging from 6 months to 40 years. 
These dermatologic disorders can be separated in manifestations that could be, or not, 
associated to immunological alterations (Table 1). 
 
Associated to immunological alterations 
Probably not associated to immunological 
alterations
Atopic dermatitis 
Seborrhoeic dermatitis 
Alopecia areata 
Vitiligo 
Infections 
- Onychomycosis 
- Scabies 
Anetoderma
Milia-like calcinosis cutis 
Acanthosis nigricans 
Syringomas elastosis perforans serpiginosa 
Leukaemia cutis  
Acrocyanosis  
Cutis marmorata 
Keratodermatoses 
Table 1. Dermatological manifestations of Down’s syndrome associates or probably not 
associated to immunological alterations 
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2. Dermatological manifestations that could be associated to immunological 
alterations 
2.1 Atopic dermatitis 
Atopic dermatitis (AD) is a chronic inflammatory skin condition that appears to involve a 
genetic defect in the proteins supporting the epidermal barrier. AD affects approximately 5-
20% of children worldwide. The incidence of AD appears to be increasing. Onset tends to 
occur during childhood and gradually diminishes with age, although it can persist or even 
appear in adults. The term AD was coined by Wise and Sulzberger in 1933 to define an 
entity characterized by dry skin, pruritus, erythematous lesions, and a chronic recurrent 
course. Currently, the terms AD and atopic eczema are used and both are acceptable. 
Its prevalence has increased 3-fold or 4- fold in recent decades in some countries. According 
to the International Study of Asthma and Allergies in Childhood, during a minimum period 
of 1 year, the prevalence of symptoms of AD in 6- or 7-year-old children presented great 
variability between different geographic areas. Thus, prevalence was almost 20% in England 
or Australia but less than 2% in China or Iran. There is a higher prevalence in urban areas 
than in rural ones in developed countries, and higher social classes are more affected.  
Regarding the disease by sex, a study of 12- to 16-year-olds found a higher prevalence 
among girls (25.7%) than among boys (17%). The onset of AD occurred during the first 6 
months of life in 45% of children, in the first year in 60%, and in the first 5 years in more 
than 85%. 
One study diagnosed AD in 56.5% of DS, and another a prevalence of more than 50%. The 
high reported prevalence of AD, in some studies, could be an overestimate and isolated 
signs such as facial dermatitis and generalized xerosis could easily be misinterpreted as AD.  
Pathogenesis of AD is complex; several factors are involved, many of which are still not well 
understood. Likewise, it has yet to be determined how these factors might interact with one 
another origin of atopic eczema seems to involve a feedback cycle: pruritus and mechanical 
damage caused by scratching leads to the production of proinflammatory cytokines 
(interleukin [IL]-1, IL-18, tumor necrosis factor, granulocyte-macrophage colony stimulating 
factor) that recruit leukocytes to the skin. 
Different leukocyte populations are activated through different processes; on induction by 
dendritic cells, the lymphocytes differentiate via the Th2 pathway; these dendritic cells also 
show increased antigen-presenting capacity and bind to the IgE-antigen complex. The IgE 
antigen complex in turn induces mast cell accumulation and activation. The activated Th2 
cells release IL-4 and IL-13, which suppress the production of antimicrobial peptides. 
Viruses, bacteria, and fungi take advantage of these reduced peptide levels, colonizing the 
skin and releasing proinflammatory products (superantigens, proteoglycans, and 
lipoteichoic acid) that amplify leukocyte activation. This activation increases the release of 
inflammatory mediators, such as proteases and IL-31, which perpetuate pruritus.  
Increased prevalence of childhood AD in developed countries has led to the appearance of 
many theories on the possible involvement of environmental factors. Increases in the 
prevalence of allergic disease probably depend more on environmental factors than on other 
individual characteristics. 
The diagnosis of AD is based on a constellation of signs and symptoms. There is no 
laboratory "gold standard" for the diagnosis of AD. In a majority of the cases, the diagnosis 
is quite easy. Establishing firm diagnostic criteria for all forms of AD is difficult due to the 
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clinical and pathophysiological heterogeneity. Atopic individuals can also suffer from other 
dermatitis or dermatoses, and because every dermatitis in an atopic individual need not be 
AD. Hanifin and Rajka for the first time proposed a systematic approach toward the 
standardization of the diagnosis of AD by incorporating three major/basic and 23 minor 
features. They suggested that a diagnosis of AD can be established if 3 of the major and 3 of 
the minor criteria are present. (Table 2). 
 
Major 
 
Minor 
 
1. Pruritus 
2. Typcial morphology and distribution: 
- Flexural lichenification or linearity in 
adults 
- Facial and extensor involvement in 
infants and children 
3. Chronic or chronically relapsing 
dermatitis 
4. Personal or family history of atopy 
(asthma, AR, atopic dermatitis) 
 
 
1. Xerosis 
2. Ichthyosis/palmar hyperlinearity/keratosis 
pilaris 
3. Immediate (type 1) skin test reactivity 
4. Elevated serum IgE 
5. Early age at onset 
6. Tendency toward cutaneous infections (esp. 
Staph. aureus and Herpes 
simplex)/impaired cell-mediated immunity 
7. Tendency toward nonspecific hand or foot 
dermatitis 
8. Nipple eczema 
9. Cheilitis 
10. Recurrent conjuntivitis 
11. Dennie-Morgan infraorbital folds 
12. Keratoconus 
13. Anterior subcapsular cataracts 
14. Orbital darkening 
15. Facial pallor/facial erythema 
16. Pityriasis alba 
17. Anterior neck folds 
18. Itch when sweating 
19. Intolerance to wool or lipid solvents 
20. Perifollicular accentuation 
21. Food intolerance 
22. Course influenced by 
environmental/emotional factors 
23. White dermographism/delayed blanch 
Table 2. Diagnostic criteria of Hanifin and Rajka Diagnosis of AD can be established if 3 of 
the major and 3 of the minor criteria are present 
In DS, the skin in infancy is usually soft, but soon becomes dry, thick, and rough, with 
patchy lichenification. The reported frequency of xerosis differs from 9.8 percent to 85 
percent in various studies. Sureshbabu et al observed disorders lichenification as the most 
common disorder, seen in 52.6% of DS patients, with a peak incidence in the 5-10 year age 
group. High incidence of AD reported by Carter et al (56.5%) and cited in some major review 
articles contrast with Sureshbabu et al study which none of subjects fulfilled the criteria of 
Hanifin and Rajka for AD.  Two studies observed 3% and 4.9% for the prevalence of AD in 
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DS using the criteria of Rajka and Hanifin, These results are in favour of the opinion that AD 
is not as common as previously thought when using the acknowledged diagnostic criteria of 
Rajka and Hanifin.  
In the treatment of AD, topical corticosteroids are considered the gold standard for 
assessment of other treatments. The potency and formulation employed depends on the area 
to be treated and the chronicity of the lesions. Areas with have undergone lichenification 
requiring stronger formulations. One application per day is sufficient, as treatment twice a 
day confers no advantage while increasing the likelihood of adverse reactions. Adverse 
reactions are well known and frequently overestimated by patients and their family 
members, even though the new formulations have a demonstrated lower risk of causing 
cutaneous atrophy than the older ones and that several studies have found a far lower 
incidence of local and systemic complications.  
Application of topical antibiotics in combination with corticosteroid therapy has advantages 
compared to topical corticosteroids. Fusidic acid appears to be the topical antibacterial 
treatment of choice, due to its low minimum inhibitory concentration and its good 
penetration. 
Topical calcineurin inhibitors have proven to be effective in the treatment of AD. Topical 
tacrolimus seems to have an efficacy similar to high-potency corticosteroids, whereas 
pimecrolimus is substantially weaker. Controlled pediatric studies have confirmed the 
superior efficacy of topical tacrolimus compared to pimecrolimus and hydrocortisone. There 
appear to be no significant differences between the response of children to concentrations of 
0.03% and 0.1%. Neither tacrolimus nor pimecrolimus cause cutaneous atrophy, but they 
can cause other adverse reactions such as local itching-burning sensation when being 
applied, which is an added discomfort for the skin of children with AD.  
Use of emollients is widely recognized as a basic measure in the treatment and prevention of 
flares of AD. It has been shown that their use in combination with topical corticosteroids 
accelerates healing and decreases the total dose of corticosteroids required to resolve the 
flare.  
Dietary restrictions have proven effective in the case of children with egg-specific IgE, but 
not for other foods which have the same effect. It seems reasonable to establish diets that 
avoid food proven to cause an allergic response using the radioallergosorbent test, although 
the most relevant test would be the challenge test, which in many cases cannot be 
performed. Psychological care is recommended to help deal with the emotional needs of 
patients with atopic dermatitis, and should be based on providing education and 
information on the clinical and preventable aspects of the disease. One study found that this 
type of intervention reduced anxiety scores. 
Short-course systemic corticosteroids are recommended to control acute flares of AD, taking 
into account that new flares are frequent after stopping treatment. Their long term use in 
children is not recommended. Little evidence exists to support using oral antihistamines in 
AD. Other systemic treatments to AD are: Cyclosporine A, azathioprine, interferon, light 
therapy or intravenous immunoglobulins. Biologic treatment has recently appeared in the 
field of dermatology and has shown some potential. 
2.2 Seborrhoeic dermatitis 
Seborrhoeic dermatitis (SD) is a common, chronic dermatoses of unknown aetiology, 
characterized by scaling and redness occurring primarily in the areas with the highest 
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concentration of sebaceous glands such as the scalp, face (mid-facial region), and certain 
areas of the trunk, such as the mid-thoracic and interscapular areas and the area around the 
buttocks. On the scalp, it generally appears first as small patches of scales, progressing to 
involve the entire scalp with exfoliation of excessive amounts of dry scales.  
It affects around 1% to 3% of the immunocompetent adult population, with a higher 
prevalence in men than women. Although it can appear at any age, the highest prevalence is 
observed in individuals aged 30 to 60 years and in the first 3 months of life in the infantile 
form of the disease. 
Clinically, the disease is characterized by erythema and flaking of the skin in the affected 
area. Lesions are well delimited, reddish, and covered with oily yellowish-white scales. 
On the scalp, in the milder form of the disease, the scales are small, dry, and whitish, and 
they detach easily and spontaneously in steady amounts. In the more severe form of the 
disease, plaques are observed that range in size from a few centimeters to areas covering a 
large part of the scalp; they are made up of thick dry scales. On the face they are found in 
the eyebrows, around the nose, at the edge of the scalp, and on the inner surface of the 
auricle. In the thorax, the lesions are rounded, well delimited, and reddish brown; they 
are located on the medial part of the chest and on the back, between the shoulder blades. 
All of these forms are associated with varying degrees of itching. In adults, the course of 
SD involves periods of remission and exacerbation, irrespective of the treatments 
administered. Outbreaks are common under conditions of emotional stress, fatigue, and 
depression. 
While the disease rarely causes serious complications, it always leads to a marked esthetic 
deterioration that leads to emotional and social difficulties for the affected individual. 
The etiology of seborrheic dermatitis is not fully understood but is known to involve various 
factors. Increased secretion by the sebaceous glands favours the development of 
microorganisms of the genus Malassezia, which are responsible for the symptoms.  
It appears more frequently in patients with neurological disorders such as Parkinson 
disease, in those suffering from depression, and in patients with AIDS. One study, by Carter 
and Jegasothy, found a 36% prevalence of SD in DS patients and another was found a 
similar prevalence (Ercis et 31%; mostly during the first year of life). SD was seen in 4.2% of 
DS by Sureshbabu et al. al. SD is commonly seen in patients with immunodeficiency. High 
prevalence of pityrosporum folliculitis in DS patients could have a pathogenic role. 
A diet rich in animal fats and lacking in vegetables, as well as alcohol consumption can also 
potentiate the appearance of lesions. Topical corticosteroids are the first choice treatment for 
SD.  Others drugs can currently be used to minimize the effects of this dermatologic disease: 
antifungals, keratolytics, tar or pyrithione derivatives, and selenium sulfate. Many of these 
treatments have been tested as both monotherapy and in combination. 
2.3 Alopecia areata 
Alopecia areata (AA) is a recurrent nonscarring type of hair loss that can affect any hair-
bearing area. Clinically, AA can manifest many different patterns. Although medically 
benign, AA can cause tremendous emotional and psychosocial distress in affected patients 
and their families.  
AA is a genetically determined, immune-mediated disorder of the hair follicle with an 
estimated lifetime risk of approximately 2%, making it one of the most common 
autoimmune diseases  
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AA is characterized by patchy hair loss on the scalp, which can eventually involve the entire 
scalp (alopecia totalis) or the entire body (alopecia universalis). The onset of the disease can be 
sudden, its progression is unpredictable, and it can be recurrent throughout life. It is 
thought that AA represents a breakdown in immune privelege with the subsequent unable 
to function of the hair follicle by T lymphocytes. AA has a deeply disturbing psychologic 
impact on affected individuals. It shows a spectrum of severity that ranges from patchy 
localized hair loss on the scalp to the complete absence of hair everywhere on the body. 
Treatment of AA may induce hair growth, but usually does not change the course of the 
disease. When treatment is stopped, hair loss recurs. Many patients with one or two small 
patches can be managed without treatment and with reassurance of the benign nature of the 
condition.  Treatment with topical and oral steroids, topical minoxidil, topical cyclosporine, 
and photo-dynamic therapy has been found no long-term benefit of these interventions. In 
patients with persistent hair loss and less than 50% scalp involvement, intralesional 
corticosteroid therapy is the first-line treatment. Patients with more than 50% hair loss can 
be treated with topical immunotherapy using diphenyl-cyclopropenone or squaric acid. 
Alopecia totalis and alopecia universalis have the worst prognosis, with fewer than 10% of 
patients recovering.  
AA occurs in approximately 0.1% of the general but a recognized association of AA with DS 
exists and it was reported between 20% to 1.4% prevalence.  Sureshbabu et al saw in 9.4% of 
DS with AA. Female predilection was observed by Carter and Jegasothy but not in other 
studies. AA was observed in 3% of DS patients in the study of Schepis et al, with the usual 
age of onset in middle childhood (5-10 years). AA, in DS patients, is usually severe and 
refractory to the standard treatments.  
2.4 Vitiligo 
Vitiligo is a hypopigmentation disorder where the loss of functioning melanocytes causes 
the appearance of white patches on the skin. It occurs when melanocytes, the cells 
responsible for skin pigmentation, die or are unable to function. The cause of vitiligo is 
unknown, but research suggests that it may arise from autoimmune, genetic, oxidative 
stress, neural, or viral causes. Vitiligo is an autoimmune disease characterized by 
melanocyte loss, which results in patchy depigmentation of skin and hair, and is associated 
with an elevated risk of other autoimmune diseases. It is a genetically complex disorder 
involving multiple susceptibility genes and unknown environmental triggers. Recent data 
provide strong evidence supporting an autoimmune pathogenesis of vitiligo. Genetic factors 
also appear to play a role in the etiopathogenesis of vitiligo as 20% to 30% of patients have a 
family history of the disorder. Vitiligo is associated with other autoimmune diseases 
(Addison´s disease, hyperthyroidism and pernicious anemia). 
Vitiligo affects 1% of the world population, but the prevalence has been reported as high as 
4% in some South Asian, Mexican and American populations. Vitiligo can develop at any 
age, but several studies report that 50% of cases appear before the age of 20 years old. Only 
one study investigated the association between vitiligo and DS found a prevalence of 1.9%.  
75% of this also had AA. However, Sureshbabu et al did not observed an incidence 
significantly higher in DS people. 
Flat areas of normal-feeling skin without any pigment appear suddenly or gradually. These 
areas have a darker border. The edges are well defined but irregular. Vitiligo most often 
affects the face, elbows and knees, hands and feet, and genits. It affects both sides of the 
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body equally. Vitiligo is more noticeable in darker-skinned people because of the contrast of 
white patches against dark skin. No other skin changes occur. Sometimes, the use of Wood's 
light can improve to see lesions. In some cases, a skin biopsy may be needed to rule out 
other causes of pigment loss. 
Vitiligo is difficult to treat. As vitiligo can have a major effect on quality of life, treatment 
can be considered and should preferably begin early when the disease is active. Current 
treatment modalities are directed towards stopping progression of the disease and 
achieving repigmentation. Therapies include corticosteroids, topical immunomodulators, 
phototherapy, surgery, combination therapies and depigmentation of normall pigmented 
skin. Topical corticosteroids can be used for localized vitiligo. The use of topical 
immunomodulators seems to be equally effective as topical steroids, especially when used 
in the face and neck region. Narrowband ultraviolet-B therapy seems to be superior to 
psoralen ultraviolet-A. Depigmentation therapy can be considered if vitiligo affects more 
than 60% to 80% of the body. 
2.5 Onychomycosis 
Onychomycosis is one of the most prevalent fungal infections in the population with a 
higher rate of treatment failures. Onychomycosis is a frequent nail disease caused by 
dermatophytes, yeasts, and nondermatophyte molds. Trichophyton rubrum, T mentagrophytes, 
and Epidermophyton floccosum are the most common etiologic agents worldwide.  
Onychomycosis may be classified into several types: distal subungual, white superficial, 
proximal subungual, endonyx, and total dystrophic. Distal subungual onychomycosis, the 
most common type, involves the nail bed and, subsequently, the nail plate. White superficial 
onychomycosis usually manifests as superficial white patches with distinct edges on the 
surface of the nail plate. Proximal subungual onychomycosis results when the fungal 
organism enters via the cuticle and the ventral aspect of the proximal nail fold. In endonyx 
onychomycosis, fungal organisms invade the nail plate without resulting nail bed 
hyperkeratosis, onycholysis, or nail bed inflammatory changes. In total dystrophic 
onychomycosis, complete dystrophy of the nail plate occurs; these changes may be primary 
or secondary. 
Diagnosis is corroborated by direct microscopic examination, culture, and histomycology. 
Treatment is based on oral antifungals. Systemic treatment for onychomycosis includes 
terbinafine, an allylamine that is primarily fungicidal, and itraconazole, a triazole that is 
primarily fungistatic. Both represent a major therapeutic advancement over griseofulvin in 
the treatment of this condition. 
For toenail infection, terbinafine is usually taken continuously for 12 weeks, whereas 
itraconazole is taken either continuously or intermittently that is 1 week in 4 weeks for the 
same period. Because therapeutic concentration of itraconazole is believed to persist in the 
nail for a considerable time after systemic treatment is stopped, intermittent therapy with 
higher daily doses to achieve and maintain therapeutic concentration might be an effective 
alternative to continuous treatment. 
Such intermittent treatment is widely used currently to treat onychomycosis and is claimed 
to be as effective for this condition as both continuous itraconazole and continuous 
terbinafine 
Although both itraconazole and terbinafine are well tolerated and highly effective drugs, 
continuous terbinafine is more effective than intermittent itraconazole at achieving 
mycological cure of toenail onychomycosis. 
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There is a higher frequency of onychomycosis in DS patients. It has been reported 
prevalence of 67,8% to 4,4%. A low incidence of infection was seen in Sureshbabu et al study 
in contrast to Carter et al who reported a high prevalence of fungal infections. Schepis et al 
also reported a relatively low figure for onychomycosis and tinea corporis. Fungal infections 
may have been over diagnosed in the past or may be caused by poor hygienic conditions.  
2.6 Scabies 
Scabies (caused by Sarcoptes scabiei) is probably one of the most common parasitic infections, 
usually spread by bodily contact, though other contaminated objects can also infect. There is 
severe itching, usually worse at night, with lesions (mostly excoriated burrows) on the 
fingerwebs, volar wrists, buttocks, Scabies is an infestation caused by human itch mite, 
Sarcoptes scabiei, which infests some 300 million persons each year and is one of the most 
common causes of itching dermatoses throughout the world. Gravid female mite measuring 
0.3 to 0.4 mm in length burrows superficially beneath the stratum corneum for a month, 
depositing two or three eggs a day. Nymphs that hatch from these eggs mature in about 2 
weeks through a series of molts and then emerge as adults to the surface of the skin, where 
they mate and subsequently reinvade the skin of the same or another host. Transfer of 
newly fertilized female mites from person to person occurs by intimate personal contact and 
is facilitated by crowding, uncleanliness and sexual promiscuity. 
The most commonly used to treatment scabies is permethrin 5% cream which applied all 
over the body. The whole family or sexual partners of infected people should be treated, 
even if they do not have symptoms. Creams are applied as a one-time treatment or they may 
be repeated in 1 week. Wash underwear, towels, and sleepwear in hot water. Vacuum the 
carpets and upholstered furniture. For difficult cases, oral Ivermectin 200-400 μgr/Kg may 
be used. 
Other creams include benzyl benzoate, sulfur in petrolatum, and crotamiton. Lindane is 
rarely used because of its side effects.  
Itching may continue for 2 weeks or more after treatment begins, but it will disappear if the 
infection is over. 
Patients with DS seem predisposed to crusted scabies.  Immunological dysfunction has been 
proposed as one factor for this propensity. However, Norwegian scabies can appear as 
isolated or epidemic conditions but no cases were recorded in some studies 
3. Other dermatological manifestations that would not be associated to 
immunological alterations 
3.1 Anetoderma 
Anetoderma is a rare benign dermatosis caused by a loss of mid-dermal elastic tissue 
resulting in well-circumscribed areas of pouchlike herniations of flaccid skin. It has been 
hypothesized that a congenital malformation of elastic fibres in this population may be 
responsible for anetoderma. 
Sureshbabu et al observed anetoderma in 3.2% of DS. Schepis et al reported 3.9% of patients 
having anetoderma in their study. It has been hypothesized that a congenital malformation 
of elastic fibers in this population may be responsible for anetoderma secondary to chronic 
folliculitis. Anetoderma is due to elastolysis probably induced by leukocytes or bacteria 
during the recurrent inflammatory events 
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3.2 Milia-like calcinosis cutis 
Milia-like idiopathic calcinosis cutis (MICC) is a rare entity. Only few cases have been 
reported so far. Two-thirds of these have been associated with Down syndrome.  
MICC is a micronodular, whitish, acral, calcified lesion. Laboratory tests are usually within 
normal range (including serum calcium and phosphate, urinary calcium and parathyroid 
hormone). The term MICC was introduced in the literature by Smith et al who described a 6-
year-old child affected by DS. Some additional cases of MICC have been reported in 
children or adolescents affected by DS. 
Milia-like idiopathic calcinosis cutis has long been regarded as a peculiar subtype of 
idiopathic calcinosis cutis. The pathogenesis of the disorder remains unclear. The 
pathogenesis of MICC in association with DS is unclear. Higher concentrations of calcium in 
sweat have been found in DS, which may lead to sweat-duct calcification 
3.3 Acanthosis nigricans 
Acanthosis nigricans (AN) is a skin disorder in which there is darker, thick, velvety skin in 
body folds and creases. Obesity can lead to AN, as can some endocrine disorders. It is often 
found in people with obesity-related diabetes Some drugs, particularly hormones such as 
human growth hormone or oral contraceptives, can also cause AN. Because AN usually 
only changes the skin's appearance, no treatment is needed. It is important, however, to 
treat any underlying medical problem that may be causing these skin changes. When AN is 
related to obesity, losing weight often improves the condition. 
AN was seen by Sureshbabu et al in 8,4% of DS. The increased incidence of AN in adults is 
more than in children, but this fact may be attributed to the fact that all these patients were 
obese with a high BMI (> 30). 
3.4 Elastosis perforans serpiginosa 
Elastosis perforans serpiginosa (EPS) is characterized clinically by papules and keratotic 
plaques and histologically by focal elastosis of the dermis and transepidermal elimination of 
abnormal elastic fibers. It is a rare skin disease classified as a primary perforating 
dermatosis similar to reactive perforating collagenosis. It was given the current 
denomination of EPS  by Dammert and Putkonen. 
The incidence of EPS has yet to be established, although looks like higher in DS people. 
Around 90% of patients develop symptoms of the disease prior to 30 years of age, the 
majority between 6 and 20 years of age; however, age at onset may range from 5 to 89 years, 
as reported in the literature. Approximately 75% of those affected are male.  
Etiopathogenesis is as yet unclear. It is believed that the focal inflammation in the dermis, 
which has a biochemical or mechanical origin, may induce the formation of epidermal and 
follicular channels to expulse abnormal elastic fibers considered irritants.  
The disorder can present with papules and erythematous or normochromic, keratotic, 
asymptomatic or pruriginous plaques grouped in an annular, arciform or serpiginous 
pattern, surrounded by satellite lesions. They have umbilicated centers from which dermal 
material is eliminated. The lesions are characteristically symmetrical except in cases 
associated with DS. 
Various forms of treatment have been indicated; however, management of the disease is 
difficult and there is no standard treatment. There have been reports of therapeutic success 
using cryotherapy with liquid nitrogen and oral isotretinoin. 
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3.5 Others 
It also has been reported higher prevalence of other skin alterations I DS patients: 
syringomas, leukaemia cutis, acrocyanosis and cutis marmorata, keratodermatoses… 
However, none all studies have observed them; for example Sureshbabu et al did not see 
syringoma, milia-like calcinosis cutis, leukemia cutis, elastosis perforans serpiginosa, 
carotenemia, or vascular instability; they referred that may relate to the fact that their study 
was not hospital based, unlike other previous studies. Other miscellaneous cutaneous 
lesions were probably coincidentally seen in the studies, concordant with that seen in the 
general population.  
4. Conclusions 
DS is increased frequency of some common dermatoses. Some dermatologic manifestation 
in DS can been in relation with their immunological alterations. Skin alterations of DS have 
been observed by few studies. Their management is equal to rest patient, but they can 
occasionally be more resistant to conventional treatment, for example AA.   
AD is one of the most frequent skin diseases associated a DS. However, perhaps this high 
association observed in first studies could be overestimated. Newer studies, which have 
used criteria of Hanifin and Rajka to diagnostic AD, does not show so higher incidence of 
AD in DS. SD can be more extensive than in other patients. 
Some immunologic skin diseases, as vitiligo and AA, have been reported with high 
incidence in DS. Also, fungal infection and scabies has been observed with higher 
prevalence in DS than rest population. However, scabies in DS could be overestimated in 
some studies with patients under epidemic conditions. 
MICC y EPS are rare skin alterations observed more frequently in DS. AN, frequently 
associated to overweight, can usually been observed in patients with IMC>30. Other 
miscellaneous cutaneous lesions were probably coincidentally seen in every study. 
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